TNBC, identified as lacking human epidermal growth factor receptor 2 (HER2) overexpression and functional expression of estrogen and progesterone receptors, is the breast cancer (BC) subtype with the poorest clinical outcome1,2. Here, ERBB2 is linked to breast cancer.